Inject Solesta: For a significant reduction in fecal incontinence episodes1,2
Dramatic reductions in fecal incontinence episodes at each time point up to 36 months from baseline1,2
42.7% reduction in the median number of FI episodes in as little as 3 months1
53.3% reduction in the median number of FI episodes through 36 months2
All three studies show an increase in number of fecal incontinence-free days2
~2X increase of incontinence free days2,3
- The mean increased number of FI free days at 6 and 12 months was greater in Solesta Treatment vs. SHAM2,3
Durable efficacy—dramatic reductions in fecal incontinence episodes at each time point up to 12 months from baseline1
Solesta was proven effective for up to 24 months following treatment in the pivotal clinical study and proof-of-concept study1
Learn more about how Solesta delivers durable efficacy
Solesta Post-Market Approval P100014; 2011.
Solesta [Package Insert]. Santa Barbara, CA: Palette Life Sciences.
Graf W, Mellgren KE, et al; for NASHA Dx study Group. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. Lancet. 2011;377(9770):997-1003.